PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer (Business Wire)
- Century Health and Arizona Gastrointestinal Associates Partner to Accelerate Real-World Evidence in IBD and MASH (PR Newswire)
- EF-YOLO: A novel AI model for high-precision detection of colorectal polyps (EurekAlert)
- Who’s winning, losing the physician practice acquisition race? (Becker’s Healthcare)
- Clinician-Industry Collaboration: A Clinical Review of Ethical, Strategic, and Practical Considerations (GI & Endoscopy News)
- Wanna Be Startin’ Somethin’? Advice for Initiating a New Line of Service (GI & Endoscopy News)
- The robotic penguin that makes endoscopy optional (Technology.org)
- Peptides, Colonoscopy, and the Inversion of Risk (Medscape)
